Remo CRO

News

Halozyme announces Phase 2 study in advanced pancreas cancer meets key endpoints

03.16 2017.

Halozyme Therapeutics, Inc. has reported topline results from the combined analysis of Stages 1 and 2 and Stage 2 alone of its HALO 202 study, a Phase 2 randomized, multi-center clinical trial of… Details

Sunovion Announces Pivotal Study Results for Novel Drug Candidate Dasotraline Demonstrating Significantly Improved Attention Deficit Hyperactivity Disorder Symptoms in Children Compared to Placebo

03.16 2017.

MARLBOROUGH, Mass. January 14, 2017 –(BUSINESS WIRE)–Sunovion Pharmaceuticals Inc. (Sunovion) today announced that results of a pivotal Phase 2/3 study (SEP360-202) evaluating novel drug candidate dasotraline in children ages 6 to 12 years with… Details

Review examines diversity in dermatology clinical trials

03.16 2017.

Racial and ethnic groups can be underrepresented in medical research. So what is the makeup of participants in randomized clinical trials of common dermatologic conditions? Details

Tetraphase Pharmaceuticals Doses First Patient In IGNITE3 Phase 3 Clinical Trial of Once-Daily IV Eravacycline in cUTI

03.16 2017.

WATERTOWN, Mass., Jan. 17, 2017 (GLOBE NEWSWIRE) — Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced dosing of the first patient in IGNITE3, the Company’s phase 3 clinical trial evaluating the efficacy and safety of once-daily… Details

Shionogi Announces Positive Top-Line Results For Cefiderocol Pivotal cUTI Clinical Trial

03.16 2017.

OSAKA, Japan and FLORHAM PARK, N.J., Jan. 12, 2017 /PRNewswire/ — Shionogi & Co., Ltd. (hereafter “Shionogi”) has announced that cefiderocol (S-649266), a novel siderophore cephalosporin in late-stage development, met the FDA pre-specified… Details